Drug intelligence / Profile preview

DWPS017

Development stage: Preclinical
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWPS017 is a small molecule therapeutic candidate being developed by Daewoong Pharmaceutical (also known as Great Bear Pharmaceutical) for the treatment of solid tumors. It is currently in the early stages of research and development, appearing in the company's oncology pipeline as a potential treatment for various malignant solid tumors. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed, the program represents part of Daewoong's effort to expand its oncology portfolio with targeted small molecule therapies.

Other names: DWPS017DWPS-017DWPS 017

Beyond the preview

Go deeper on DWPS017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWPS017.

Explore the full profile